- Home
- IKT vs TRUE Comparison
IKT vs TRUE Comparison
Compare IKT & TRUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IKT
- TRUE
- Stock Information
- Founded
- IKT 2008
- TRUE 2005
- Country
- IKT United States
- TRUE United States
- Employees
- IKT N/A
- TRUE N/A
- Industry
- IKT Biotechnology: Pharmaceutical Preparations
- TRUE Computer Software: Programming Data Processing
- Sector
- IKT Health Care
- TRUE Technology
- Exchange
- IKT Nasdaq
- TRUE Nasdaq
- Market Cap
- IKT 131.6M
- TRUE 114.6M
- IPO Year
- IKT 2020
- TRUE 2014
- Fundamental
- Price
- IKT $1.66
- TRUE $1.71
- Analyst Decision
- IKT Buy
- TRUE Buy
- Analyst Count
- IKT 2
- TRUE 5
- Target Price
- IKT $8.00
- TRUE $3.19
- AVG Volume (30 Days)
- IKT 126.7K
- TRUE 265.8K
- Earning Date
- IKT 08-13-2025
- TRUE 08-04-2025
- Dividend Yield
- IKT N/A
- TRUE N/A
- EPS Growth
- IKT N/A
- TRUE N/A
- EPS
- IKT N/A
- TRUE N/A
- Revenue
- IKT N/A
- TRUE $179,356,000.00
- Revenue This Year
- IKT N/A
- TRUE $7.54
- Revenue Next Year
- IKT N/A
- TRUE $11.02
- P/E Ratio
- IKT N/A
- TRUE N/A
- Revenue Growth
- IKT N/A
- TRUE 10.18
- 52 Week Low
- IKT $1.12
- TRUE $1.05
- 52 Week High
- IKT $4.20
- TRUE $4.62
- Technical
- Relative Strength Index (RSI)
- IKT 35.43
- TRUE 59.54
- Support Level
- IKT $1.91
- TRUE $1.52
- Resistance Level
- IKT $2.07
- TRUE $1.65
- Average True Range (ATR)
- IKT 0.11
- TRUE 0.09
- MACD
- IKT -0.03
- TRUE 0.02
- Stochastic Oscillator
- IKT 0.00
- TRUE 91.30
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
About TRUE TrueCar Inc.
TrueCar Inc is a data-driven online platform operating on common technology infrastructure, powered by proprietary data and analytics. It also customizes and operates its platform for affinity group marketing partners, including financial institutions like PenFed and American Express; membership-based organizations like Consumer Reports, AARP, Sam's Club, and AAA; and employee buying programs for large enterprises such as IBM and Walmart. The Company has one operating segment, with three distinct service offerings: Dealer products and services, OEM incentives, and other.